CD4 and COVID-19: Furthermore, we explored potential differences and similarities in the breadth, distribution, magnitude and phenotype of CD4+ T‐cell responses directed against the SARS‐CoV‐2 spike glycoprotein between vaccine recipients, COVID‐19 patients and patients who experienced both ways of immunisation.